Advanced Cancer Pain Management Market Summary

• According to DelveInsight, Advanced Cancer Pain Management Market is expected to grow at a decent CAGR by 2032.
• Advanced Cancer Pain Management Companies are WEX Pharmaceuticals Inc., Jazz Pharmaceuticals, Nobelpharma Co., Ltd, and Tetra Bio-Pharma Inc.

Advanced Cancer Pain Management Market Insight and Trends

• In August 2025, Purdue Pharma (US) announced a strategic partnership with a leading telehealth provider to integrate digital health solutions into its pain management offerings. This move is likely to enhance patient engagement and adherence to treatment protocols, reflecting a broader trend towards digitalization in healthcare. By leveraging telehealth, Purdue Pharma (US) aims to provide more personalized care, which could improve patient outcomes and satisfaction.
• In September 2025, Johnson & Johnson (US) launched a new pain management initiative focused on educating healthcare professionals about the safe use of opioids. This initiative underscores the company's commitment to responsible prescribing practices and aligns with regulatory trends emphasizing the need for comprehensive education in pain management. By positioning itself as a leader in responsible opioid use, Johnson & Johnson (US) may strengthen its market presence and build trust with healthcare providers and patients alike.
• In October 2025, Bristol-Myers Squibb (US) revealed its plans to invest in a new research facility dedicated to the development of innovative pain management therapies. This investment is indicative of the company's long-term commitment to addressing the unmet needs in cancer pain management. By fostering a culture of innovation, Bristol-Myers Squibb (US) is likely to enhance its competitive edge and contribute to the advancement of treatment options available to patients.
• As of October 2025, the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in pain management solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their capabilities and market reach. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable approach to cancer pain management.

Factors affecting Advanced Cancer Pain Management Market Growth

Rising Global Cancer Burden

Increasing incidence of advanced-stage cancers leads to higher prevalence of severe cancer-related pain, driving the need for effective pain management therapies and devices.

Growing Demand for Palliative & Supportive Care

Greater emphasis on improving quality of life for late-stage cancer patients boosts adoption of analgesics, interventional procedures, neuromodulation, and non-opioid pain management solutions.

Advancements in Novel & Targeted Analgesic Therapies

New formulations (long-acting opioids, abuse-deterrent formulations), non-opioid analgesics, cannabinoid research, and nerve-targeting therapies contribute to market expansion.

Increasing Use of Minimally Invasive Pain Management Procedures

Techniques such as nerve blocks, neuroablation, intrathecal drug delivery systems, and spinal cord stimulators are gaining acceptance due to strong clinical outcomes.

Growing Awareness Among Patients & Caregivers

Educated patient populations and caregiver involvement help increase diagnosis and treatment of cancer pain, especially in emerging markets.

Strong Focus on Multimodal Pain Management

Combination therapy models integrating pharmacological, interventional, psychological, and rehabilitation approaches improve overall adoption of comprehensive care solutions.

DelveInsight's "Advanced Cancer Pain Management - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Advanced Cancer Pain Management, historical and forecasted epidemiology as well as the Advanced Cancer Pain Management market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Advanced Cancer Pain Management market report provides current treatment practices, emerging drugs, Advanced Cancer Pain Management market share of the individual therapies, current and forecasted Advanced Cancer Pain Management market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Advanced Cancer Pain Management treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Advanced Cancer Pain Management Disease Understanding and Treatment Algorithm

The DelveInsight Advanced Cancer Pain Management market report gives a thorough understanding of the Advanced Cancer Pain Management by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Advanced Cancer Pain Management Overview

Pain is a common occurrence in cancer patients, especially when the disease reaches an advanced stage, with estimates suggesting that it affects over 70% of these individuals. This pain significantly contributes to their overall physical and emotional well-being.

The pain experienced by cancer patients can be attributed to several factors. Firstly, it can be a direct result of the damage caused by tumors, which may destroy or apply pressure to surrounding tissues, bones, or nerves. Additionally, tumors can obstruct hollow body structures like the digestive system, blood vessels, and lymph vessels, further exacerbating pain.

Furthermore, cancer treatments themselves can lead to pain. Surgical procedures are the most common cause, but chemotherapy, immunotherapy, and radiation therapy can also induce pain in some cases.

The National Institutes of Health report varying rates of pain prevalence depending on the stage of cancer and treatment. Pain is reported in 39.3% of patients after curative treatment, 55.0% during anticancer treatment, and 66.4% in advanced, metastatic, or terminal disease stages.

Mild and moderate pain in cancer patients often manifest as muscle pain, bone pain, or discomfort resulting from surgical incisions. Relief for such pain can be achieved through the use of non-opioid medications like acetaminophen (Tylenol) and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen (Advil). These non-opioid pain relievers are typically prescribed alongside opioids and other therapies to provide more effective pain relief.

In cases of moderate to severe pain, opioids are highly effective medications for managing cancer-related pain. These opioids encompass drugs like morphine, fentanyl, codeine, oxycodone, hydromorphone, and methadone. There is sometimes concern about the potency of morphine, but opioids can be combined with non-opioid drugs like acetaminophen or NSAIDs to manage moderate pain. For severe pain, opioids can be used in conjunction with other medications and therapies.

Breakthrough cancer pain (BTcP) is characterized by sudden, intense, and brief pain episodes that occur on top of a stable baseline of pain control in cancer patients. BTcP significantly impairs patients' quality of life and their ability to carry out everyday tasks. The standard treatment for BTcP involves the use of fast-acting opioids and immediate-release oral opioids, such as morphine sulfate, hydromorphone, and oxycodone.

Advanced Cancer Pain Management Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Advanced Cancer Pain Management

Advanced Cancer Pain Management Treatment

It covers the details of conventional and current medical therapies available in the Advanced Cancer Pain Management market for the treatment of the condition. It also provides Advanced Cancer Pain Management treatment algorithms and guidelines in the United States, Europe, and Japan.

Advanced Cancer Pain Management Epidemiology

The Advanced Cancer Pain Management epidemiology division provide insights about historical and current Advanced Cancer Pain Management patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Advanced Cancer Pain Management Report

The Advanced Cancer Pain Management epidemiology covered in the report provides historical as well as forecasted Advanced Cancer Pain Management epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

• In a study by Jiang et al. (2019), of the identified 4526 cancer survivors, 1648 reported having chronic pain and 768 reported having HICP, representing approximately 5.39 million and 2.51 million cancer survivors, respectively, in the US population.
• In a study by Everdingen et al. (2016), pain prevalence rates were 39.3% after curative treatment; 55.0% during anticancer treatment; and 66.4% in advanced, metastatic, or terminal disease. Moderate to severe pain was reported by 38.0% of all patients.
• In a study by Marieke et al. (2016), pain severity resulted in a 38.0% prevalence of moderate to severe pain. With reference to types of cancer, lower pain prevalence rates were demonstrated in prostate cancer compared to head and neck, lung, and breast cancer. 
• In a study by Rustøen et al. (2013), high intensity of breakthrough cancer pain was described by 75.5% of the patients, and the painful crises can be exacerbated by either predictable or unpredictable events.

Country Wise- Advanced Cancer Pain Management Epidemiology

The epidemiology segment also provides the Advanced Cancer Pain Management epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Advanced Cancer Pain Management Drug Analysis

Drug chapter segment of the Advanced Cancer Pain Management market report encloses the detailed analysis of Advanced Cancer Pain Management marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Advanced Cancer Pain Management clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Advanced Cancer Pain Management Marketed Drugs

The Advanced Cancer Pain Management market report provides the details of the marketed product available for Advanced Cancer Pain Management treatment.

Advanced Cancer Pain Management Emerging Drugs

The Advanced Cancer Pain Management market report provides the details of the emerging therapies under the late and mid-stage of development for Advanced Cancer Pain Management treatment.

PPP011/QIXLEEF: Tetra Bio-Pharma

PPP011/QIXLEEF (Tetra Bio-Pharma) is a botanical inhaled drug product that with its innovative and proprietary dosing data, provides fast acting relief from pain, offering patients a viable, safer, and non-opioid option for pain management. It is being evaluated in two Phase II trials. One is REBORN trial which is a head-to-head study against an opioid treatment in the management of short and frequent episodes of incapacitating pain (breakthrough pain) requesting immediate release opioid treatment in patients living with cancer. In June 2021, an approved amended protocol opened the recruitment to cancer patients with breakthrough pain who are treated with either oral morphine sulfate immediate release, oral hydromorphone immediate release, or oral oxycodone immediate release. The other is PLENITUDE trial to evaluate safety and efficacy of the drug for the uncontrolled pain relief in patients with advanced cancer. In November 2021 the company announced positive initial clinical data from the ongoing Phase II clinical trials and in March 2022, the company received the response letter for a Type C meeting with the US FDA for QIXLEE. Further, the FDA provided guidance on the Company's nonclinical safety program required to submit a marketing application.

Halneuron: WEX Pharmaceuticals

Halneuron (WEX Pharmaceuticals) is WEX’s primary product under development. Halneuron’s active pharmaceutical ingredient is Tetrodotoxin (“TTX”), a small molecule known to block voltage-gated sodium channels on neurons and prevents pain by inhibiting the initiation and conduction of nerve impulses in the peripheral nervous system which is associated with pain. Halneuron is administered by subcutaneous injection and has been tested on over 700 people to date. It has been tested on patients with moderate to severe cancer pain as well as patients with chemotherapy-induced neuropathic pain and clinical data to date has shown varying degrees and duration of pain relief. WEX is in process of launching its pivotal Phase III trial for Halneuron to treat Chemotherapy-Induced Neuropathic Pain in the United States and Canada. Also the drug is in Phase III clinical development for the treatment of cancer related pain in several other regions.

Advanced Cancer Pain Management Market Outlook

The Advanced Cancer Pain Management market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Advanced Cancer Pain Management market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Advanced Cancer Pain Management market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Advanced Cancer Pain Management market in 7MM is expected to change in the study period 2019-2032.

Key Findings from Advanced Cancer Pain Management Market Report

This section includes a glimpse of the Advanced Cancer Pain Management market in 7MM.

Limited companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow ACPM patients to live a more normal life. However, there are several drugs in pipeline that focuses on the management of cancer related pain. Companies like Terta Bio-pharma (PPP011/QIXLEEF), WEX Pharmaceuticals (Halneuron), Intellia Therapeutics (NTLA-2002), Pharvaris Netherlands B.V. (PHA-022121), and others will fuel market in upcoming years.

The United States Advanced Cancer Pain Management Market Outlook

This section provides the total Advanced Cancer Pain Management market size and market size by therapies in the United States.

EU-5 Countries Advanced Cancer Pain Management Market Outlook

The total Advanced Cancer Pain Management market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Advanced Cancer Pain Management Market Outlook

The total Advanced Cancer Pain Management market size and market size by therapies in Japan is also mentioned.

Advanced Cancer Pain Management Drugs Uptake

This section focusses on the rate of uptake of the potential ACPM drugs recently launched in the Advanced Cancer Pain Management market or expected to get launched in the market during the study period 2019-2032. The analysis covers Advanced Cancer Pain Management market uptake by drugs; patient uptake by therapies; and sales of each drug.   

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Advanced Cancer Pain Management Clinical Trial Activities

The Advanced Cancer Pain Management market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Advanced Cancer Pain Management key players involved in developing targeted therapeutics.

Advanced Cancer Pain Management Pipeline Development Activities

The Advanced Cancer Pain Management market report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Advanced Cancer Pain Management emerging therapies.

Reimbursement Scenario in Advanced Cancer Pain Management

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on Advanced Cancer Pain Management

To keep up with current market trends, we take KOLs and SME's opinion working in Advanced Cancer Pain Management domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Advanced Cancer Pain Management market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Advanced Cancer Pain Management Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Advanced Cancer Pain Management Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Advanced Cancer Pain Management Market Report

• The Advanced Cancer Pain Management market report covers the descriptive overview of Advanced Cancer Pain Management, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Advanced Cancer Pain Management epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Advanced Cancer Pain Management are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Advanced Cancer Pain Management market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Advanced Cancer Pain Management market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Advanced Cancer Pain Management market

Advanced Cancer Pain Management Market Report Highlights

• In the coming years, Advanced Cancer Pain Management market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cancer Pain Management R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Advanced Cancer Pain Management. Launch of emerging therapies will significantly impact the Advanced Cancer Pain Management market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Advanced Cancer Pain Management
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Advanced Cancer Pain Management Market Report Insights

• Advanced Cancer Pain Management Patient Population
• Advanced Cancer Pain Management Therapeutic Approaches
• Advanced Cancer Pain Management Pipeline Analysis
• Advanced Cancer Pain Management Market Size and Trends
• Advanced Cancer Pain Management Market Opportunities
• Impact of upcoming Advanced Cancer Pain Management Therapies

Advanced Cancer Pain Management Market Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Advanced Cancer Pain Management Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Advanced Cancer Pain Management Market
• Advanced Cancer Pain Management Drugs Uptake

Advanced Cancer Pain Management Market Report Assessment

• Current Advanced Cancer Pain Management Treatment Practices
• Advanced Cancer Pain Management Unmet Needs
• Advanced Cancer Pain Management Pipeline Product Profiles
• Advanced Cancer Pain Management Market Attractiveness
• Advanced Cancer Pain Management Market Drivers and Barriers

Key Questions Answered in the Advanced Cancer Pain Management Market Report

Advanced Cancer Pain Management Market Insights

• What was the Advanced Cancer Pain Management market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Advanced Cancer Pain Management total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Advanced Cancer Pain Management market size during the forecast period (2019-2032)?
• At what CAGR, the Advanced Cancer Pain Management market is expected to grow in 7MM during the forecast period (2019-2032)?
• What would be the Advanced Cancer Pain Management market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Advanced Cancer Pain Management market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Advanced Cancer Pain Management Epidemiology Insights

• What is the disease risk, burden and unmet needs of the Advanced Cancer Pain Management?
• What is the historical Advanced Cancer Pain Management patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Advanced Cancer Pain Management in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Advanced Cancer Pain Management?
• Out of all 7MM countries, which country would have the highest prevalent population of Advanced Cancer Pain Management during the forecast period (2019-2032)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Advanced Cancer Pain Management treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Advanced Cancer Pain Management in the USA, Europe, and Japan?
• What are the Advanced Cancer Pain Management marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Advanced Cancer Pain Management companies are developing therapies for the treatment of Advanced Cancer Pain Management?
• How many Advanced Cancer Pain Management therapies are developed by each company for Advanced Cancer Pain Management treatment?
• How many are Advanced Cancer Pain Management emerging therapies in mid-stage, and late stage of development for Advanced Cancer Pain Management treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Advanced Cancer Pain Management therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Cancer Pain Management and their status?
• What are the key designations that have been granted for the emerging therapies for Advanced Cancer Pain Management?
• What are the global historical and forecasted Advanced Cancer Pain Management market?

Reasons to buy the Advanced Cancer Pain Management Market Report

• The Advanced Cancer Pain Management market report will help in developing business strategies by understanding trends shaping and driving the Advanced Cancer Pain Management market
• To understand the future market competition in the Advanced Cancer Pain Management market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Advanced Cancer Pain Management in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming Advanced Cancer Pain Management companies in the Advanced Cancer Pain Management market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Advanced Cancer Pain Management market
• To understand the future market competition in the Advanced Cancer Pain Management market